( March 14, 2025, 3:43 PM EDT) -- KANSAS CITY, Kan. — A final approval hearing for a $73 million settlement reached with Mylan NV, Mylan Specialty LP and Mylan Pharmaceuticals Inc. (collectively, Mylan) to end claims that they conspired with others in an attempt to delay entry of generic competitors for the EpiPen XE "EpiPen" epinephrine autoinjector (EAI) into the market is scheduled for May 9 in a Kansas federal court, the judge overseeing the case announced....